Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 26;391(12):1159-1162.
doi: 10.1056/NEJMc2409512. Epub 2024 Sep 16.

Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma

Kohei Shitara  1 , Manish A Shah  2 , Florian Lordick  3 , Eric Van Cutsem  4 , David H Ilson  5 , Samuel J Klempner  6 , Yoon-Koo Kang  7 , Sara Lonardi  8 , Yi-Ping Hung  9 , Kensei Yamaguchi  10 , Peter Enzinger  11 , Tomoko Nakajima  12 , Maria Matsangou  12 , Ying Cao  12 , Ran Li  12 , Diarmuid Moran  12 , Rupesh Pophale  12 , Mok Oh  12 , Radhika Ranganath  12 , Jaffer A Ajani  13 , Rui-Hua Xu  14
Affiliations

Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma

Kohei Shitara et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Progression-free Survival and Overall Survival in the Combined Analysis.
Shown are results from a combined analysis of two placebo-controlled trials of zolbetuximab. Panel A shows the Kaplan–Meier plot for progression-free survival, and Panel B the Kaplan–Meier plot for overall survival. The median follow-up for progression-free survival was 18.2 months (95% CI, 15.4 to 20.9) in the zolbetuximab group and 17.9 months (95% CI, 14.8 to 23.7) in the placebo group. The median follow-up for overall survival was 32.7 months (95% CI, 29.5 to 34.3) in the zolbetuximab group and 31.8 months (95% CI, 29.7 to 34.3) in the placebo group. In both panels, tick marks indicate censored data.
See this image and copyright information in PMC

References

    1. Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 2023;401:1655–68. - PubMed
    1. Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. Nat Med 2023;29:2133–41. - PMC - PubMed
    1. Lordick F, Van Cutsem E, Shitara K, et al. Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials. ESMO Open 2024. August 14 (Epub ahead of print). - PMC - PubMed

Publication types

MeSH terms